Author: Customer Service

Majority ownership of Vireo Health of New York to transfer to MWBE-led Ace Ventures; partnership reinforces long-term alignment with New York’s social equity framework MINNEAPOLIS, April 03, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (“Vireo”) (CSE: VREO; OTCQX: VREOF) today announced a strategic partnership with Ace Venture of NY, LLC (“Ace”), a New York-based Minority & Women-Owned Business Enterprise led by lifelong New Yorker Steven Acevedo, to establish what is expected to become New York’s first scaled social equity operator emerging from the state’s first minority-owned vertically integrated medical cannabis license. The partnership was developed under the leadership of Chief Executive Officer John Mazarakis and reflects Vireo’s commitment to advancing New York’s vision for a responsible, inclusive, and community-oriented...

EFFINGHAM, Ill., April 03, 2026 (GLOBE NEWSWIRE) — Midland States Bancorp, Inc. (Nasdaq: MSBI) announced today that it will issue its first quarter 2026 financial results after market close on Thursday, April 23, 2026. Along with the press release announcing the financial results, the Company will publish an investor presentation that will be available on the Webcasts and Presentations page of its investor relations website. About Midland States Bancorp, Inc. Midland States Bancorp, Inc. is a community-based financial holding company headquartered in Effingham, Illinois, and is the sole shareholder of Midland States Bank. As of December 31, 2025, the Company had total assets of approximately $6.51 billion, and its Wealth Management Group had assets under administration of approximately $4.48 billion. The Company provides a full...

Office of the CEO Established to Oversee Business Operations  Board Forms Transition Committee and Commences CEO Search NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced leadership and governance changes, including the establishment of an Office of the CEO and the formation of a new Transition Committee of the Board of Directors (“the Board”). These actions follow Tara Comonte’s departure from the Company, effective March 31, 2026.  The Company’s Board of Directors has initiated a comprehensive search for a permanent successor with the support of a leading executive search firm. During the transition period, the Office of the CEO will oversee business operations and execution of the Company’s...

WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 685,718 shares of the Company’s common stock to five newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of March 31, 2026 (the “Effective Date”). The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.68 per share, which is equal to the closing price of the Company’s common stock on the Effective Date....

HOUSTON, April 03, 2026 (GLOBE NEWSWIRE) — Impact BioMedical Inc. (NYSE American: IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from Grassi & Co., CPAs, P.C. that contains a “going concern” qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company’s financial statements for the year ended December 31, 2025. Again, this announcement does not represent any change or amendment to the Company’s financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2025. Separately, Impact Biomedical...

Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technology Results from ongoing Phase 1/2 study in patients with FTD-GRN expected by the end of 2026SOUTH SAN FRANCISCO, Calif., April 03, 2026 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it has received notification from Takeda of its decision to terminate the collaboration agreement between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN). The decision was driven by strategic considerations and is not related to efficacy or safety data. DNL593 is an investigational progranulin replacement therapy utilizing Denali’s Protein TransportVehicle™ (PTV) to deliver progranulin across the blood-brain barrier to the brain for the...

PASCAGOULA, Miss., April 03, 2026 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding division recently welcomed former U.S. Sen. Sam Nunn, his wife, Colleen Nunn, and their daughter and ship sponsor Michelle Nunn, for a visit to the shipyard. The visit included a construction update and tour of the future USS Sam Nunn (DDG 133), a Flight III Arleigh Burke-class destroyer named in honor of the senator, and marked their return to Ingalls following the ship’s keel authentication ceremony. “It was an honor to welcome Sen. Nunn and Michelle Nunn to Ingalls to see first-hand the progress taking place on DDG 133 and to highlight the ship’s advancing construction path toward launch,” Ingalls Shipbuilding President Brian Blanchette said. “Our shipbuilders take tremendous pride in building a ship that will carry Sen. Nunn’s name and...

Proposed appointment to the Board of Directors at the Annual General Meeting on May 21st, 2026: Thierry Fournier candidate director – Appointed censor with immediate effect   _PRESS RELEASE_ Paris, April 3rd, 2026 – The Nexans Board of Directors has appointed Thierry Fournier as censor with a view to proposing his appointment as member of the Board of Directors to the shareholders’ general meeting to be held on May 21st, 2026. As censor, Thierry Fournier will attend Board of Directors meetings with a consultative role, and the Board will benefit immediately from his extensive experience and expertise. The Internal Regulations of the Board will be applicable to him in full. Thierry Fournier has served as Chief Executive Officer of Roquette since 2025. Before joining Roquette  he was Senior Vice President and CEO for Southern Europe, the...

BRONX, N.Y., April 03, 2026 (GLOBE NEWSWIRE) — Ponce Bank, National Association, the banking subsidiary of Ponce Financial Group, Inc., has been recognized by S&P Global Market Intelligence as one of the Top 50 Best-Performing U.S. Community Banks of 2025 in the $3 billion to $10 billion asset category, ranking #40 nationally. This recognition underscores the Bank’s strong financial performance while reaffirming its longstanding commitment to community impact and inclusive growth. S&P Global Market Intelligence’s annual rankings evaluate financial institutions based on key performance indicators including returns, growth, funding, and balance sheet strength, with a particular emphasis on risk profile and long-term stability. Ponce Bank’s placement reflects a balanced approach to performance—delivering solid financial results...